

OT

TFW

1643

PTO/SB/21 (09-04)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Total Number of Pages in This Submission

Application Number

10/051,652

Filing Date

January 15, 2002

First Named Inventor

Manuel L. Penichet

Group Art Unit

1643

Examiner Name

Hon Sang

Attorney Docket Number

407J-001700US

ENCLOSURES (check all that apply)

- ☐ Fee Transmittal Form
☐ Fee Attached
- ☐ Amendment / Response
☐ After Final
☐ Affidavits/declaration(s)
- ☐ Extension of Time Request
- ☐ Express Abandonment Request
- ☒ Information Disclosure Statement
- ☐ Certified Copy of Priority Document(s)
- ☐ Response to Missing Parts/ Incomplete Application
☐ Response to Missing Parts under 37 CFR 1.52 or 1.53

- ☐ Assignment Papers (for an Application)
- ☐ Drawing(s)
- ☐ Licensing-related Papers
- ☐ Petition Routing Slip (PTO/SB/69) and Accompanying Petition
- ☐ Petition to Convert to a Provisional Application
- ☐ Power of Attorney, Revocation Change of Correspondence Address
- ☐ Terminal Disclaimer
- ☐ Small Entity Statement
- ☐ Request for Refund

- ☐ After Allowance Communication to Group
- ☐ Appeal Communication to Board of Appeals and Interferences
- ☐ Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
- ☐ Proprietary Information
- ☐ Status Letter
- ☒ Additional Enclosure(s) (please identify below):

PTO-1449 form, cited references, Statement under 37 CFR 1.97(d)-(e)(1), copy of EP Search Report and receipt acknowledgment postcard

Authorization to Charge Deposit Account

Please charge Deposit Account No. 50-0893 for any additional fees associated with this paper or during the pendency of this application, including any extensions of time for consideration of the documents enclosed.

Remarks

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm or Individual name

Paul Littlepage, Reg. No. 48,581, Quine Intellectual Property Law Group, P.C.

Signature

Date

June 30, 2006

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on

Typed or printed name

Evelyn Gomez

Signature

Date

June 30, 2006



I hereby certify that this correspondence is
being deposited with the United States
Postal Service as first class mail in an envelope addressed to:
Commissioner for Patents, P.O. Box 1450
Alexandria, VA 22313-1450,
On June 30, 2006

Quine Intellectual Property Law Group, P.C.

By 

Evelyn Gomez

Attorney Docket No. 407J-001700US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:
Manuel L. Penichet, *et al.*

Application No.: 10/051,652
Filed: January 15, 2002-

For: ANTIBODY-AVIDIN FUSION
PROTEINS AS CYTOTOXIC DRUGS

Examiner: Hon Sang

Art Unit: 1643

Statement under 37 C.F.R. §1.97(d)-(e)(1)


Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

CERTIFICATION

I hereby certify that each item of information contained in the information
disclosure statement was first cited in a communication from a foreign patent office in a
counterpart foreign application not more than three months prior to the filing of the
information disclosure statement.

Respectfully submitted,


Paul Littlepage, Reg. No. 48,581

QUINE INTELLECTUAL PROPERTY LAW GROUP, P.C.
P.O. Box 458
Alameda, CA 94501
Tel: (510) 337-7871 / Fax: (510) 337-7877



I hereby certify that this correspondence is being deposited with the United States Postal Service first class mail in an envelope addressed to:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on June 30, 2006

QUINE INTELLECTUAL PROPERTY LAW GROUP, P.C.

By

Evelyn Gomez
Evelyn Gomez

Attorney Docket No. 407J-001700US
Client Ref. No. 2002-100-1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Manuel L. Penichet, et al.

Application No.: 10/051,652

Filed: January 15, 2002

For: ANTIBODY-AVIDIN FUSION
PROTEINS AS CYTOTOXIC DRUGS

Examiner: Hon Sang

Art Unit: 1643

INFORMATION DISCLOSURE
STATEMENT UNDER 37 CFR § 1.97 and
§ 1.98

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450


Sir:

The references cited on attached form PTO-1449 are being called to the attention of the Examiner. Copies of the references are enclosed. Also, enclosed is a copy of European Search Report for corresponding European Application No. 03710672.1. It is respectfully requested that the cited information be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

As provided for by 37 CFR 1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.

This IDS is being filed after the mailing date of the Final Office Action, but within 3 months of the information first being cited in a communication from a foreign patent office for a counterpart foreign application. Please deduct \$180.00, pursuant to 37 CFR §1.17(p), from the undersigned's Deposit Account No. 50-0893. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,



Paul Littlepage
Reg. No. 48,581

QUINE INTELLECTUAL PROPERTY LAW GROUP, P.C.
P.O. BOX 458
Alameda, CA 94501
(510) 337-7871
Fax (510) 337-7877

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A-B/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application Number	10/051,652
Filing Date	January 15, 2002
First Named Inventor	Manuel L. Penichet
Group Art Unit	1643
Examiner Name	Hon Sang
Attorney Docket Number	407J-001700US
Date Submitted	June 30, 2006

U.S. PATENT DOCUMENTS

Examiner Initials	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code (if known)			

FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
		Office	Number	Kind Code (if known)				

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
	1	GHETIE et al. "Homodimerization of tumor-reactive Monoclonal Antibodies Markedly Increases their Ability to Induce Growth Arrest or Apoptosis of Tumor Cells", Proc. Natl. Acad. Sci. USA, Vol. 94, pp. 7509-7514, (1997).	
	2	GREEN, "Avidin and Streptavidin", Methods in Enzymology, Academic Press, Inc. Vol. 184, pp. 51-67, (1990).	
	3	LESLEY et al., "Inhibition of Cell Growth by Monoclonal Anti-Transferrin Receptor Antibodies", Mol. and Cell. Biology, Vol. 8, pp. 1814-1821, (1985).	
	4	LITTLE et al., "Of mice and men: Hybridoma and Recombinant Antibodies", Immunology Today, Vol. 21, No. 8, pp. 364-370, (2000).	
	5	KEMP et al., "Effects of Anti-Transferrin Receptor Antibodies on the Growth of Neoplastic Cells", Pathobiology, Vol. 60, No. 1, pp. 27-32, (1992).	
	6	KIPRIYANOV et al., "Affinity Enhancement of a Recombinant Antibody: Formation of complexes with Multiple Valency by a Single-Chain Fv Fragment-core Streptavidin Fusion", Protein Engineering, Vol. 9, No. 2, pp. 203-211, (1996).	
	7	TAETLE et al., "Mechanisms of Growth Inhibition by Anti-Transferrin Receptor Monoclonal Antibodies", Cancer Research, Vol. 46, No. 4, pp. 1759-1763, (1986).	
	8	STONE et al., "A Tetravalent Single Chain Antibody-Streptavidin Fusion Protein Induces Apoptosis in Human B-Lymphoma Cells", Proceeding of the Amer. Assoc. for Cancer Research Annual Meeting, Vol. 43, page 881, (2002).	
	9	WOLFF et al, Monoclonal Antibody Homodimers: Enhanced Antitumor Activity in Nude Mice", Cancer Research, Vol. 53, No. 11, pp. 2560-2565, (1993).	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.